We recently compiled a list of the 10 Best New Penny Stocks To Buy Now. In this article, we are going to take a look at where Boundless Bio, Inc. (NASDAQ:BOLD) stands against the other new penny stocks.
Fears of a US recession are growing, sending stock markets down, and investors around the world are on edge. The US Bureau of Labor Statistics (BLS) released July job figures that were worse than anticipated, revealing only 114,000 new jobs generated in July compared to the predicted 175,000. These data alarmed investors, as did the disappointing latest earnings from tech giants. As a result, the manufacturing industry in the US had an eight-month low in activity and the unemployment rate reached a three-year high of 4.3% due to a decline in new contracts.
Monday was the worst day for Wall Street in nearly two years as key indexes fell on worries about a US recession. The average of the 500 largest publicly traded companies plummeted 3% to 5,186.33. However, the 500 large companies are still up more than 10% for the year.
Chris Weston, of the US online stockbroker Pepperstone, said global markets were “at a truly important juncture”. “What really matters now is whether money managers and traders feel sentiment has become too pessimistic, or if this deleveraging and risk aversion manifests into even higher volatility and drawdown.
Opinions among analysts regarding the gravity of the problem differ. James St Aubin, chief investment officer at Ocean Park Asset Management, “We’re witnessing the fallout from the curse of high expectations,”, while Art Hogan, chief market strategist at B. Riley Wealth, said that markets may be overreacting. He stated:
“This isn’t a Category 3 hurricane, but we are seeing how markets react to signs that the economy is normalising after turning hot in the first half of this year.” “Markets can find themselves overreacting and investors [latch] on to anything as an excuse to take profits.”
The 500 large companies have gained more than 15% this year, despite recent setbacks.
The market’s anxiety may be heightened by the possibility that fewer initial public offerings (IPOs) might take place this year. However, 154 IPOs were listed on the US stock market in 2023, but this was 85% fewer than the record-breaking 1,035 IPOs in 2021 and 15% fewer than the 181 IPOs in 2022, 82.5% fewer than in 2021. IPOs totaling 6,203 have occurred between 2000 and 2024. 2009 had the fewest, with just 62. With 1035 IPOs in total, 2021 established an all-time record, surpassing the previous high of 480 in 2020.
George Chan, EY Global IPO Leader, says:
“As 2024 unfolds, participants in the IPO market are entering uncharted territory. IPO candidates are influenced by the recent pivot in investors’ preference toward proven profitability in an altered interest rate landscape, and are doing this while facing the intricate dynamics of an intensified geopolitical climate and the buzz around AI. To succeed in this shifting environment, IPO prospects must remain flexible and prepared to seize the right moment for their public debuts.”
Recent data from EY Global IPO Trends Q2 2024 show that in 2024, the US IPO markets saw a strong start that increased global proceeds. On the other hand, the Asia-Pacific area had a poor start, which affected the worldwide volume overall. In the first half of 2024, the industrials (21%), technology (19%), and materials (11%) markets led the way in global IPO issuance, with India dominating in terms of deal volume. Meanwhile, the technology (21%), health and life sciences (17%), and industrials (15%) markets topped the IPO proceeds rankings, with the US attracting the lion’s share of these sectors. As the home to many of the world’s leading technology and healthcare companies, the US has a strong ecosystem for startups. Driven by favorable market conditions, expectation of interest rate cuts, and innovations in artificial intelligence (AI), IPO deal values have skyrocketed in both these markets. Moreover, a handful of large deals contributed to a 67% increase in proceeds from IPOs in the US in the first half of 2024.
Methodology:
In this article, we first used a stock screener to list down all stocks trading under $5 (as of the writing of this article) with high institutional ownership. We have limited our selection to stocks that went IPO over the past year. From the resultant dataset, we chose 10 stocks with the highest number of hedge fund investors, using Insider Monkey’s database of 920 hedge funds in Q1 2024 to gauge hedge fund sentiment for stocks. We have used the stocks’ market cap as a tie-breaker in case two or more stocks have the same number of hedge funds invested.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here)
A biotechnologist in a laboratory testing an Immuno-oncology treatment.
Boundless Bio, Inc. (NASDAQ:BOLD)
Number of Hedge Fund Investors: 22
Boundless Bio, Inc. (NASDAQ:BOLD), a clinical-stage oncology firm, creates cancer therapies to meet the unmet needs of patients with oncogene-amplified tumors by targeting extrachromosomal DNA. BBI-355, an oral checkpoint kinase 1 inhibitor, is the company’s main product candidate. Patients with oncogene-amplified malignancies are participating in a Phase 1/2 clinical trial for this drug. The company is also working on the ecDTx 3 program, which targets a kinesin implicated in the biological mechanism for ecDNA segregation, and BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistant gene amplifications.
The company went public on March 28, 2024. Meanwhile, elite funds are piling into this stock as well, with hedge fund positions increasing from 0 in Q4 2023 to 22 in Q1 2024, giving us a clear hint that investors are bullish on Boundless Bio, Inc. (NASDAQ:BOLD)’s stock. Hence, BOLD is one of the best new penny stocks to buy now.
Boundless Bio, Inc. (NASDAQ:BOLD) is still enrolling patients in the POTENTIATE study for its flagship asset, BBI-355. The initial dosage administered to patients with malignancies exhibiting resistance gene amplifications in the Phase 1/2 STARMAP clinical trial of BBI-825
Zachary Hornby, President and Chief Executive Officer of Boundless Bio, stated in the Q1 2024 earnings:
“It has been an exciting quarter at Boundless Bio. The Phase 1/2 POTENTIATE trial of BBI-355, our potentially best-in-class, oral, selective CHK1 inhibitor, advanced into initial combination therapy modules evaluating BBI-355 together with an EGFR inhibitor or an FGFR inhibitor in patients with tumors harboring EGFR or FGFR oncogene amplifications, respectively. We also dosed the first patient with our second ecDNA-directed therapy (ecDTx), BBI-825, a first-in-class oral, selective RNR inhibitor, which marks the company’s rapid growth and transition into a multi-asset, clinical-stage oncology company” “With the completion of our recent IPO, we have the capital to take the next steps toward delivering on the promise of our ecDTx, a potential new vertical in cancer therapeutics.”
As of March 31, 2024, the sum of cash, cash equivalents, and short-term investments was $104.9 million, a 57.20% increase from the same quarter the previous year. Furthermore, in early April 2024, Boundless Bio concluded its first public offering (IPO), selling 6,250,000 shares of its common stock for a total gross proceeds of $100.0 million. Boundless Bio anticipates that its present financial position, with a pro forma cash position of approximately $200 million, will support operations through significant clinical data milestones and into the second half of 2026.
The global market for solid tumor cancer treatments was valued at $104.88 billion in 2022 and is expected to grow to $532 billion by 2032, according to Precedence Research. This provides a large, addressable market for Boundless Bio’s technologies.
Analyst Andrew Berens of Leerink Partners recommended a buy and set a $25.00 price objective in April. As per 3 analysts, the company has an average price target of $23 and an upside potential of 669.49% from the current stock price of $2.99. Analysts have rated BOLD as a “strong buy.”
Overall BOLD ranks 2nd on our list of the best new penny stocks to buy. While we acknowledge the potential of BOLD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BOLD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Analyst Sees a New $25 Billion “Opportunity” for NVIDIA and Jim Cramer is Recommending These 10 Stocks in June.
Disclosure: None. This article is originally published at Insider Monkey.
